Your session is about to expire
← Back to Search
Olaparib +/− Atezolizumab for Advanced Breast Cancer
Study Summary
This trial is testing olaparib with or without atezolizumab to treat non-HER2-positive breast cancer that has spread and is not able to be surgically removed or has metastasized.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 154 Patients • NCT02184195Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is Olaparib a new medication?
"548 clinical trials are currently underway to study Olaparib. 99 of those trials are in the critical third stage. The majority of these studies originate from New york, but there are 27896 locations running experiments for this treatment across the globe."
Does this clinical trial break new ground in the medical field?
"548 clinical trials for Olaparib are recruiting patients in 2161 different cities, located across 75 countries. The first ever study was completed in 2005 and involved 98 individuals. That initial research project cleared Phase 1 drug approval thanks to the sponsoring from AstraZeneca. In the 16 years since then, 321 more studies have been carried out."
At how many different physical sites can patients participate in this trial?
"This trial is based out of Moffitt Cancer Center-International Plaza in Tampa, Florida, University of Colorado Hospital in Aurora, Colorado, and Smilow Cancer Hospital Care Center-Fairfield in Fairfield, Connecticut with 36 other satellite locations."
What is the official stance of the FDA on Olaparib?
"Olaparib has received a safety score of 2. This is due to it being a Phase 2 trial, where there is evidence suggesting it is safe but not necessarily effective."
What is the approved use for Olaparib?
"Olaparib has shown to be an effective mode of pharmacotherapy for small cell lung cancer (sclc) and malignant neoplasms."
Are there any open positions in this clinical trial for new patients?
"This particular clinical trial is no longer looking for patients. The first posting was on November 15th, 2016 and the last edit was September 2nd, 2022. There are 4728 other trials currently searching for breast cancer patients and 548 trials specifically for Olaparib that have open recruitment."
Share this study with friends
Copy Link
Messenger